Mineralys Therapeutics (MLYS) Q1 2026 earnings summary

Executive summary

• FDA accepted the NDA for lorundrostat for hypertension, assigning a PDUFA target date of December 22, 2026, marking a major regulatory milestone.

• Lorundrostat's NDA is supported by six late-stage clinical trials, including two pivotal registrational trials, demonstrating significant blood pressure reduction, good tolerability, and durable response.

• Pre-commercial activities are underway, including market access, sales preparation, and expansion of commercial infrastructure and field-based teams.

• Ongoing market research indicates strong prescriber, payer, and patient interest in lorundrostat, especially for resistant hypertension.

• No revenue generated to date; operations funded by equity offerings and other financings.

Financial highlights

• Cash, cash equivalents, and investments totaled $646.1 million as of March 31, 2026, down from $656.6 million at year-end 2025.

• R&D expenses were $24.4 million, down from $37.9 million year-over-year, mainly due to the completion of pivotal trials.

• G&A expenses rose to $21 million from $6.6 million year-over-year, driven by higher professional fees and increased headcount.

• Net loss for Q1 2026 was $39.3 million, an improvement from $42.2 million in Q1 2025.

• Other income increased to $6 million from $2.2 million year-over-year, reflecting higher interest income.

Outlook and guidance

• Current cash position is expected to fund planned clinical, regulatory, and operational activities into 2028.

• Anticipates increased expenses for regulatory, commercial launch, and organizational expansion as lorundrostat approaches potential approval.

• Expects continued net losses and negative cash flows until product commercialization.

• Continued investment in physician advocacy, payer engagement, and market access planning ahead of potential launch.

• FDA review of lorundrostat NDA ongoing, with potential approval and launch targeted for late 2026.